TriplePoint Venture Growth BDC Corp. (TPVG)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 57 | 101 | 13 | 6 | 71 | 97 | 84 | 90 |
| Operating profit | $m | 76 | 55 | ||||||
| Net profit | $m | 35 | 77 | -20 | -40 | 32 | 49 | 39 | 35 |
| EPS reported | $ | 1.22 | 0.99 | ||||||
| Operating cashflow per share | $ | -1.42 | -0.72 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -1.42 | -0.72 | ||||||
| Free cash flow | $m | -57 | -29 | ||||||
| Net debt | $m | 449 | 430 | ||||||
| Book value equity | $m | 354 | 353 | ||||||
| Book value per share | $ | 8.78 | 8.69 | ||||||
| Number of shares | m | 40.28 | 40.6 | ||||||
| DPS (TTM paid) | $ | 1.08 | 1.06 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 5.36 | 4.83 | ||||||
| P/B LTM | x | 0.74 | 0.75 | ||||||
| P/S LTM | x | 2.71 | 3.13 | ||||||
| P/FCF LTM | x | -4.62 | -9.05 | ||||||
| EV/EBITDA LTM | x | 9.40 | 12.88 | ||||||
| EV/Sales LTM | x | 7.33 | 7.62 | ||||||
| Earnings Yield LTM | % | +18.66% | +20.70% | ||||||
| FCF Yield | % | -21.65% | -11.05% | ||||||
| Quality | |||||||||
| ROE | % | +13.92% | +10.97% | ||||||
| ROIC | % | +9.02% | +6.90% | ||||||
| Operating margin | % | +77.90% | +65.62% | ||||||
| Gross margin | % | +83.51% | +76.04% | ||||||
| FCF/Sales | % | -58.67% | -34.53% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +48.78% | +20.73% | ||||||
| Sales Growth YoY | % | +36.55% | +18.36% | ||||||
| Net Income Growth YoY | % | +53.55% | +20.87% | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | +136.31% | +72.51% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +15.67% | +18.04% | ||||||
| Dividend Growth | % | -22.86% | -24.29% | ||||||
| Payout Ratio | % | +84.00% | +89.99% | ||||||
| FCF/Debt | x | -0.12 | -0.07 | ||||||
| Net Debt/EBITDA | x | 5.93 | 7.78 | ||||||
| EBIT/Net interest | x | 2.86 | 1.73 | ||||||
| Net debt/market cap | % | +1.78% | +2.10% | ||||||
| Net debt/Equity | x | 1.27 | 1.22 | ||||||
| Gross debt/equity | x | 1.33 | 1.26 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
TriplePoint Venture Growth BDC Corp. (TPVG) functions as a business development company, primarily concentrating its investments on growth-stage enterprises backed by venture capital. The firm's core offering involves providing debt financing solutions to companies within the venture growth ecosystem. These solutions encompass a diverse range of products, such as growth capital loans, customized and secured credit facilities, equipment financing, and revolving lines of credit. Additionally, TPVG engages in direct equity investments. Its investment strategy targets companies operating in key sectors, including e-commerce, entertainment, technology, and life sciences. Within the technology sphere, the areas of specific interest are broad, covering cybersecurity, wireless communication equipment, network systems and software, business application software, conferencing solutions, big data analytics, cloud computing, data storage, electronics, energy efficiency, hardware, information services, internet and media, networking, semiconductors, various software categories (including Software-as-a-Service), and other related technological subsectors. For life sciences, TPVG focuses on biotechnology, biofuels/biomass, diagnostic testing and bioinformatics, drug delivery systems, drug discovery, healthcare information systems, healthcare services, medical/surgical/therapeutic devices, pharmaceuticals, and other related fields. The size of TPVG's investments varies based on the type of financing: growth capital loans typically range from $5 million to $50 million, equipment financings are between $5 million and $25 million, and revolving loans generally fall between $1 million and $25 million. Direct equity investments, conversely, are usually from $0.1 million to $5 million, and are structured to not exceed 5% of the portfolio company's total equity. The debt financing instruments are commonly structured as lines of credit, and the company also employs warrants and secured loans in its funding approach. TPVG aims to achieve targeted returns of 10% to 18%. A distinctive aspect of its investment policy is that it does not seek board representation in the companies it finances.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
TriplePoint Venture Growth BDC Corp. (TPVG)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
TriplePoint Venture Growth BDC Corp. (TPVG) functions as a business development company, primarily concentrating its investments on growth-stage enterprises backed by venture capital. The firm's core offering involves providing debt financing solutions to companies within the venture growth ecosystem. These solutions encompass a diverse range of products, such as growth capital loans, customized and secured credit facilities, equipment financing, and revolving lines of credit. Additionally, TPVG engages in direct equity investments. Its investment strategy targets companies operating in key sectors, including e-commerce, entertainment, technology, and life sciences. Within the technology sphere, the areas of specific interest are broad, covering cybersecurity, wireless communication equipment, network systems and software, business application software, conferencing solutions, big data analytics, cloud computing, data storage, electronics, energy efficiency, hardware, information services, internet and media, networking, semiconductors, various software categories (including Software-as-a-Service), and other related technological subsectors. For life sciences, TPVG focuses on biotechnology, biofuels/biomass, diagnostic testing and bioinformatics, drug delivery systems, drug discovery, healthcare information systems, healthcare services, medical/surgical/therapeutic devices, pharmaceuticals, and other related fields. The size of TPVG's investments varies based on the type of financing: growth capital loans typically range from $5 million to $50 million, equipment financings are between $5 million and $25 million, and revolving loans generally fall between $1 million and $25 million. Direct equity investments, conversely, are usually from $0.1 million to $5 million, and are structured to not exceed 5% of the portfolio company's total equity. The debt financing instruments are commonly structured as lines of credit, and the company also employs warrants and secured loans in its funding approach. TPVG aims to achieve targeted returns of 10% to 18%. A distinctive aspect of its investment policy is that it does not seek board representation in the companies it finances.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free